Injectable Administration News
-
Showcase
ARAI-2PAM Barda Procurement Award
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
-
Showcase
FDA Emerging Technology Program
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
-
Showcase
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
-
Showcase
Zeneo® Adrenaline: A New Innovative Formulation
Anaphylactic shock is an absolute medical emergency. When anaphylactic shock is suspected, emergency services must be called and emergency first aid administered immediately. The only first-line treatment for anaphylactic shock is injectable adrenaline1. In the USA: 1.6% to 5.1% of the population has experienced anaphylactic shock, 1% of hospitalizations are caused by it, 0.1% of patients ...
By Crossject
-
CD Formulation Introduces Microneedle Patch Innovations for Enhanced Drug Delivery Efficiency
CD Formulation, a leading innovator in drug delivery technologies, has recently introduced a series of groundbreaking microneedle patch innovations that promise to revolutionize the way drugs are administered. Microneedle patches are a novel drug delivery system that utilizes tiny needles to painlessly penetrate the skin's outer layer and deliver medication directly into the bloodstream. This ...
-
CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency
CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...
-
Pushing the Boundaries of Drug Delivery: CD Formulation's Breakthrough Microsphere and Microneedle Technologies
As medicine continues to advance in this new era, drug delivery methods have been revolutionized to enhance patient comfort, improve treatment outcomes and ensure effective delivery of therapeutic compounds. CD Formulation, a leading pharmaceutical research and development company, has recently unveiled a series of cutting-edge technologies that will further revolutionize and redefine the realm ...
-
Reorganized Collection of Pharmaceutical Excipients Now Released at CD Formulation
Since its launch, the pharmaceutical excipients provided by CD Formulation have gained significant popularity among customers worldwide. To enhance the search process, CD Formulation has recently reorganized its collection of pharmaceutical excipients and unveiled these changes on its website. With a focus on improving drug delivery systems and dosage forms, the company aims to offer innovative ...
-
CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...
-
CD Formulation Newly Launches 100+ Raw Materials for Preparation of Microspheres and Microneedles
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance ...
-
Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model
Abstract: We previously reported the development of a novel formulation of an ultra-long-acting local anesthetic based on bupivacaine encapsulated in large multivesicular liposomes (Bupisomes) embedded in hydrogel. This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we ...
-
Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
By Bayer AG
-
Differences Between Spinal Blocks & Epidurals
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
-
Active Implants Receives FDA Breakthrough Device Designation for NUsurface Meniscus Implant
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced that the NUsurface® Meniscus Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration. The NUsurface® Meniscus Implant is the first “artificial meniscus” to be marketed in Europe and, if cleared by the FDA, would be the first ...
-
Active Implants SUN Clinical Trial for Persistent Knee Pain Now Underway in San Diego
Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s SUN (Safety Using NUsurface) trial is now underway in San Diego. Dr. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the ...
-
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye ...
-
Creative Medical Technology Announces Positive Top-Line Results for StemSpine Pilot Study
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® ...
-
What to Expect for an Epidural Injection
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...
-
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of ...
-
RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is ...
By RevBio Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you